Vorolanib and Cadonilimab for untreated advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, Vorolanib and Cadonilimab, for people with advanced or metastatic clear cell kidney cancer who have not had prior treatment. It aims to see if the combination shrinks the cancer and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have clear cell renal cell carcinoma, a specific type of kidney cancer.
- Your cancer must be advanced (cannot be fully removed by surgery) or has spread to other parts of the body (stage IV).
- You should not have received any prior systemic treatment (like chemotherapy or targeted therapy) for your kidney cancer, except for one type of treatment before surgery if it was given more than 6 months ago.
- You must be between 18 and 75 years old.
- You need to have at least one tumor that can be measured on scans, and your overall health status must be good (Karnofsky score of 70 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs together—vorolanib (a pill that targets blood vessels in tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer)—for people with advanced kidney cancer whose prior immunotherapy combination stopped working.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
This trial tests a combination of two drugs (tivozanib and nivolumab) for people with advanced kidney cancer that is not clear cell type. It aims to see if this drug pair can shrink or slow the cancer.
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
This trial tests a new combination of two oral drugs (vorolanib plus everolimus) versus the standard drug sunitinib in people with advanced clear cell kidney cancer that got worse after immunotherapy alone or with a targeted therapy. The goal is to see if the new combination works better.
This trial tests a combination of two drugs — voronib and everolimus — for people with clear cell kidney cancer whose previous targeted therapy and immunotherapy have stopped working. The goal is to see if this new combination can help when other treatments have failed.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.